- Molecular NameBusulfan
- Synonymbusulfan; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Sulfabutin; Sulphabutin; Tetramethylene Dimethane Sulfonate; Tetramethylenester Kyseliny Methansulfonove
- Weight246.304
- Drugbank_IDDB01008
- ACS_NO55-98-1
- Show 3D model
- LogP (experiment)-0.5
- LogP (predicted, AB/LogP v2.0)-0.48
- pkaN/A
- LogD (pH=7, predicted)-0.48
- Solubility (experiment)69 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.55
- LogSw (predicted, AB/LogsW2.0)4.09
- Sw (mg/ml) (predicted, ACD/Labs)6.93
- No.of HBond Donors0
- No.of HBond Acceptors6
- No.of Rotatable Bonds7
- TPSA103.5
- StatusFDA approved
- AdministrationOral, parenteral
- PharmacologyA chemotherapy drug that is a cell cycle non-specific alkylating antineoplastic agent (slows the growth of cancer cells). More specifically it belongs to a subclass of alkylating agents known as alkyl sulfonates.
- Absorption_value100.0
- Absorption (description)Completely absorbed from the gastrointestinal tract.
- Caco_2N/A
- Bioavailability70.0
- Protein binding8.35
- Volume of distribution (VD)0.99 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life2.6 h
- ExcretionIt is mainly excreted in the urine as metabolites; about 1% of a dose is excreted in the urine unchanged in 24 h.
- Urinary Excretion1
- Clerance4.5 ml/min/kg
- ToxicitySigns of overdose include allergic reaction, unusual bleeding or bruising, sudden weakness or unusual fatigue, persistent cough, congestion, or shortness of breath; flank, stomach or joint pain; pronounced nausea, vomiting, diarrhea, dizziness, confusion, or darkening of the skin, chills, fever, collapse, and loss of consciousness.
- LD50 (rat)N/A
- LD50 (mouse)N/A